Efficacy, Safety and Tolerability of Ribavirin Monotherapy Followed by Combined Treatment With Ribavirin and Hydroxychloroquine in Patients Infected With Hepatitis C

NCT01833845 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

4

Enrollment

INDUSTRY

Sponsor class

Stopped due to failure to recruit subjects

Conditions

Hepatitis C

Interventions

DRUG: Ribavirin
DRUG: Hydroxychloroquine

Sponsor

BioLineRx, Ltd.